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Open aa b s t r a c t
HMG-CoA reductase inhibitors, or statins, are widely used as cholesterol-lowering agents in the
treatment of dyslipidemias. Statins have also been reported to have pleiotropic effects, independent of
their effects on cholesterol synthesis, possibly through inhibition of the monomeric G proteins Ras and
Rho, which are able to signal through ERK and Rho kinase activities, respectively. We have previously
demonstrated that inhibition of ERK activation enhances b-adrenoceptor-mediated vasodilatation in
the porcine isolated coronary artery. As statins can also inhibit ERK activation, the initial aim of this
study was to determine whether statins have a similar inﬂuence on b-adrenoceptor-evoked vasodilata-
tion. Segments of porcine distal coronary artery were mounted in a Mulvany wire myograph and
bathed in Krebs–Henseleit buffer gassed with 95% O2/5% CO2 and maintained at 37 1C. Tissues were
pre-contracted with the thromboxane mimetic U46619 prior to cumulative concentration–response
curves to the b-adrenoceptor agonist salbutamol in the absence or presence of simvastatin (1, 5 or
10 mM), pravastatin (10 mM), or lovastatin (10 mM). Simvastatin inhibited the salbutamol-induced
relaxation of the coronary artery. Similar effects were seen with lovastatin, but not pravastatin or the
sodium salt of simvastatin. Simvastatin, but not pravastatin also inhibited the relaxations to the Ca2þ-
activated Kþ channel opener NS1619 and the KATP channel opener pinacidil. Unexpectedly, these data
indicate that, rather than enhancing b-adrenoceptor-mediated vasodilatation, lipophilic statins impair
these responses. This is likely to be due to effects on Kþ channels.
& 2012 Published by Elsevier B.V. Open access under CC BY license.1. Introduction
Statins are widely-used drugs for the treatment of hypercho-
lesterolaemia. By inhibiting 3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA) reductase, statins prevent the conversion of
HMG-CoA to mevalonic acid, an early precursor of cholesterol,
thereby inhibiting the biosynthesis of cholesterol. Statins have
also been reported to have pleiotropic effects, independent of a
reduction in cholesterol levels and these effects may underlie the
ability of statins to improve cardiovascular health in patients
without raised plasma cholesterol (Bonetti et al., 2003).
The pleiotropic effects of statins could be due to a reduction
in the activity of other intracellular signalling pathways. In
addition to lowering cholesterol, statins also decrease levels
of intermediates of the mevalonate pathway, including the
isoprenoids farnesyl pyrophosphate and geranylgeranyl pyro-
phosphate. Both of these isoprenoids are involved in post-
translational modiﬁcation of multiple proteins, including theax: þ44 115 82 30142.
(R.E. Roberts).
ccess under CC BY license.monomeric G proteins Ras and Rho. This post-translational
modiﬁcation enables translocation of the monomeric G proteins
to the cell membrane, where they are activated (Lane and Beese,
2006). For example, simvastatin inhibits proliferation of human
smooth muscle cells by preventing the farnesylation of Ras
(Negre-Aminou et al., 1997).
The regulation of vascular smooth muscle tone is a complex
process based on the balance between vasoconstricting and
vasodilating substances. Activation of Rho kinase and extracellu-
lar signal-regulated kinase (ERK), for example, is associated with
vasoconstriction (Roberts, 2004), whilst on the other hand,
increases in the levels of nitric oxide result in vasodilatation.
Since Rho and Ras are upstream of Rho kinase and ERK activities,
respectively, statins would be expected to inhibit vasoconstric-
tion. Previous studies have demonstrated that lipophillic statins,
including simvastatin and lovastatin induce an acute relaxation of
isolated blood vessels directly (Bergdahl et al., 2003; Mraiche
et al., 2005; Nagaoka et al., 2007). On the other hand, hydrophilic
statins such as pravastatin do not induce relaxation (Bergdahl
et al., 2003; Mraiche et al., 2005).
We have previously shown that inhibition of ERK activation
results in the enhancement of b-adrenoceptor-mediated
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negatively regulates b-adrenoceptor function. As statins have
been shown to inhibit ERK activation in vascular smooth muscle
(Tristano et al., 2007), the initial aim of this investigation was to
determine whether simvastatin also enhance b-adrenoceptor-
mediated vasodilatation.2. Methods
2.1. Tissue preparation
Hearts from pigs of both sexes were obtained from a local
abattoir and transported back to the laboratory in ice-cold
Krebs–Henseleit buffer, previously gassed with 95% O2, 5% CO2.
The composition of Krebs–Henseleit solution, in mM, was as
follows: NaCl, 128; KCl, 4.8; MgSO4, 1.1; NaHCO3, 25; KH2PO4,
1.2; D-glucose, 12; CaCl2, 1.25. Anterior descending coronary
arteries were then dissected out from the hearts as previously
described (Uhiara et al., 2009). The vessels were stored overnight
at 4 1C in Krebs–Henseleit solution containing Ficoll (2%) pre-
gassed with 95% O2, 5% CO2. Previous experiments have demon-
strated that these conditions have negligible effect on contractile
and vasodilator function in isolated blood vessels (Lot and
Wilson, 1994).
The following day, distal sections of coronary arteries were
dissected into 2 mm ring segments and mounted on a Mulvany,
four-channel wire myograph attached to a PC computer via a
PowerLab data acquisition system (ADInstruments Ltd., UK). The
5 mL baths contained Krebs–Henseleit solution maintained at
37 1C and gassed with 95% O2, 5% CO2. A tension of 2.5 g was
applied to each ring segment prior to investigation. In some
experiments, the endothelium was removed by rubbing the
lumen of the arteries with a ﬁne pair of forceps prior to mounting
in the myograph.
2.2. Experimental procedure
After challenging artery rings to KCl (60 mM) as previously
described (Uhiara et al., 2009), the rings were incubated in Krebs–
Henseleit buffer for 45 min in either the absence or presence of
various statins: simvastatin (1 mM, 5 mM or 10 mM), lovastatin
(10 mM), pravastatin (10 mM) and simvastatin Naþ (5 mM). Pre-
vious studies have demonstrated that simvastatin and lovastatin
have an acute effect on vascular responses in isolated blood
vessels at these concentrations (Bergdahl et al., 2003; Mraiche
et al., 2005; Nagaoka et al., 2007). Control tissues received vehicle
only (0.1% v/v dimethyl sulphoxide (DMSO) for 10 mM lovastatin
and 0.05% v/v DMSO for 5 mM simvastatin). The tissues were
precontracted to approximately 65–80% of the peak KCl contrac-
tile response using the thromboxane mimetic U46619 (10–
50 nM), before relaxations were induced using cumulative con-
centrations of the b2-adrenoceptor agonist salbutamol (10 nM–
30 mM). In a further set of experiments, forskolin (1 nM–3 mM)
was applied to U46619-pre-contracted vessels to assess receptor-
independent vasodilatation. In order to assess the effect of statins
on Kþ channel-dependent responses, relaxations were induced
using cumulative concentrations of the selective opener of large-
conductance calcium-activated Kþ channels (BKCa) NS1619
(10 nM–30 mM) or the selective opener of ATP-sensitive Kþ
channels (KATP) pinacidil (1 nM–30 mM). Alternatively, tissues
were incubated with simvastatin (5 mM) after pre-contraction
with KCl.
In all experiments there was no signiﬁcant difference between
the levels of pre-contraction evoked by U46619 in vehicle- and
drug-exposed vessel segments.2.3. Statistical analyses
The data were analysed using the computer program Prism
(GraphPad Software, Inc., La Jolla, CA, USA). Relaxations were
expressed as a percentage change from the U46619-induced
contraction and were expressed as means7S.E.M of n experiments,
where n represents the number of different animals. Statistical
comparisons were made using ANOVA followed by a Bonferroni
post-hoc test. Unpaired Student’s t-tests were used to assess
differences between the levels of U46619-evoked pre-contraction.
A P-valueo0.05 was considered statistically signiﬁcant.
2.4. Reagents and compounds
9,11-Dideoxy-9a,11a-methanoepoxy prostaglandin F2a (U46619),
forskolin—Axxora (Bingham, Nottinghamshire, UK); salbutamol,
simvastatin, lovastatin, pravastatin—Tocris Bioscience (Bristol,
UK); 1,3-dihydro-1-[2-hydroxy-5-(triﬂuoromethyl)phenyl]-5-(tri-
ﬂuoromethyl)-2H-benzimidazol-2-one (NS1619), pinacidil—Sigma
(Poole, Dorset, UK); simvastatin Naþ—Calbiochem (Nottingham,
UK). The remaining chemicals were obtained from Sigma (Poole,
Dorset, UK).3. Results
3.1. The effect of statins on b-adrenoceptor-mediated relaxation
Cumulative addition of the b2-adrenoceptor agonist salbuta-
mol (10 nM–30 mM) to U46619-precontracted porcine coronary
artery (PCA) segments evoked concentration-dependent relaxa-
tions with an maximum relaxation of 10073% (mean7S.E.M.) of
the U46619-induced contraction and a pEC50 value of 5.970.1
(n¼16). Addition of simvastatin to the tissues had no effect on
basal tone. Pre-incubation with 1 mM simvastatin had no effect on
the relaxations to salbutamol (Fig. 1A). On the other hand, pre-
incubation with 5 mM simvastatin produced a marked inhibition
of the relaxations to salbutamol (Fig. 1A). In tissues incubated
with 10 mM simvastatin, there was no relaxation to salbutamol
(data not shown). Similarly, lovastatin (10 mM; Fig. 1B) reduced
relaxations to salbutamol, whereas neither pravastatin (10 mM;
Fig. 1C) nor simvastatin Naþ (5 mM; Fig. 1D) altered the relaxa-
tion characteristics of salbutamol. Removal of the endothelium
had no signiﬁcant effect on the inhibition of the salbutamol
relaxations with 5 mM simvastatin (76.974.5% relaxation to
30 mM salbutamol in control compared to 48.075.3% relaxation
in the presence of 5 mM simvastatin, n¼7).
3.2. The effect of statins on forskolin-induced relaxation
b-Adrenoceptors cause relaxation of blood vessels through
activation of adenylyl cyclase and an increase in cAMP. In order
to determine whether simvastatin could be inhibiting the b-
adrenoceptor-relaxation through inhibition of cAMP-mediated
relaxations, we investigated the effect of simvastatin on the
relaxation responses to the adenylyl cyclase activator forskolin.
As can be seen in Fig. 2, simvastatin did not alter relaxations at
any concentration of forskolin.
3.3. The effect of simvastatin on relaxations induced by Kþ channel
openers
A previous study has demonstrated that simvastatin inhibits
large-conductance calcium-activated Kþ channel (BKCa) activity
in porcine isolated coronary artery smooth muscle cells (Seto
et al., 2007). As b-adrenoceptors are able to cause relaxations




























































































































Fig. 1. The effects of statins on salbutamol-induced relaxations. The effect of pre-incubation with simvastatin (A), lovastatin (B), pravastatin (C) or simvastatin Naþ (D) on
salbutamol-induced relaxations in porcine coronary artery segments pre-contracted with the thromboxane mimetic U46619. Relaxation responses are shown as
means7S.E.M. (n¼4–9). *** indicates Po0.001 (two-way ANOVA followed by Bonferroni post-hoc test).































Fig. 2. The effect of simvastatin on relaxations evoked by forskolin. The effect of
pre-incubation with 5 mM simvastatin on forskolin-induced relaxations in porcine
coronary artery segments pre-contracted with the thromboxane mimetic U46619.
Relaxation responses are shown as means7S.E.M. (n¼4–5). Vehicle controls are
represented by open circles and simvastatin by closed squares.
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determined whether simvastatin also inhibited the relaxations
to the BKCa channel opener NS1619. NS1619 caused a concentra-
tion-dependent relaxation of the porcine coronary artery with an
estimated pEC50 value of 5.470.1 (n¼5; Fig. 3A). Simvastatin
(5 mM) signiﬁcantly inhibited relaxations to NS1619 (Fig. 3A). As a
comparison we also determined the effect of simvastatin on the
relaxations to the KATP channel opener pinacidil. Pinacidil caused
a concentration-dependent relaxation of the coronary artery with
a pEC50 of 5.870.1 and a maximum relaxation of 11776% (n¼4).
Like the NS1619 relaxations, relaxations elicited by pinacidil were
also inhibited by simvastatin (Fig. 3B). In comparison, pravastatin
had no effect on the relaxations to either pinacidil or NS1619
(Fig. 4A and B). Relaxations to salbutamol were reduced after pre-
contraction with KCl (relaxation to 30 mM salbutamol 39.179.4%,
n¼6). Under these conditions, simvastatin had no further inhibi-
tory effect on the salbutamol-induced relaxation (relaxation
to 30 mM salbutamol in the presence of 5 mM simvastatin
37.874.4%, n¼6).4. Discussion
The main ﬁnding from this study is that simvastatin inhibits
b2-adrenoceptor-mediated relaxations of porcine coronary artery.
In a previous study we demonstrated that b-adrenoceptor-
mediated relaxations in the porcine coronary artery can be






































































Fig. 3. The effect of simvastatin on relaxations evoked by Kþ channel openers. The
effect of pre-incubation with 5 mM simvastatin on relaxations to NS1619 (A) and
pinacidil (B) in pre-contracted porcine coronary artery segments. Relaxation
responses are shown as means7S.E.M. (n¼5–6 and n¼3–4, respectively). *
indicates Po0.05 and **indicates Po0.01 (two-way ANOVA followed by Bonfer-
roni post-hoc test).

























































Fig. 4. The effect of pravastatin on relaxations evoked by Kþ channel openers The
effect of 10 mM pravastatin on relaxations evoked by the Kþ channel openers
NS1619 (A) and pinacidil (B) in pre-contracted porcine coronary artery segments.
Relaxation responses are shown as means7S.E.M. (n¼5–6 and n¼3–4,
respectively.
C.O. Uhiara et al. / European Journal of Pharmacology 690 (2012) 158–163 161enhanced by inhibition of ERK activation (Uhiara et al., 2009). By
inhibiting HMG-CoA reductase, statins reduce the production of
mevalonate, leading to a general inhibition of cholesterol synth-
esis (Buhaescu and Izzedine, 2007). Inhibition of HMG-CoA
reductase by statins also reduces the production of the isopre-
noids farnesyl pyrophosphate and geranylgeranyl pyrophosphate.
The low molecular weight, monomeric G proteins Rac-1, Ras and
Rho undergo post-translational modiﬁcation involving the attach-
ment of an isoprenoid (prenylation), allowing them to be asso-
ciated with the plasma membrane (Zhang and Casey 1996; Lane
and Beese., 2006), which is required for activity. As Ras is
upstream of ERK activation, statins would be expected to inhibit
ERK activity. Indeed, simvastatin inhibits ERK activation in iso-
lated vascular smooth muscle cells (Tristano et al., 2007). There-
fore, as inhibitors of ERK activation, statins would be predicted to
enhance b-adrenoceptor-mediated relaxations, based on our pre-
vious study. Rather unexpectedly, however, in the present study,
we found that incubation with simvastatin had the opposite effect
with 5 mM simvastatin causing a substantial inhibition of the b-
adrenoceptor-mediated relaxation. Indeed, at 10 mM simvastatin,
there was no detectable relaxation to salbutamol. Pre-incubation
with lovastatin also caused a reduction in the salbutamol-induced
relaxation, while pravavstatin and simvastatin Naþ were without
effect on salbutamol-evoked relaxations.The difference in the effects of simvastatin and lovastatin
versus pravastatin may be related to the lipophilicity of the
compounds. Simvastatin and lovastatin are both lipophilic,
whereas pravastatin is hydrophilic (Serajuddin et al., 1991). This
may affect the ability of the compounds to cross the plasma
membrane and hence inhibit the intracellular signalling cascades.
This is supported by the data using the sodium salt of simvastatin
(Fig. 1D), which is charged and hence unable to cross the plasma
membrane. This compound, unlike simvastatin itself, had no
effect on b-adrenoceptor-mediated responses. Similar differences
in the effects of lipophilic versus hydrophilic statins have been
reported elsewhere. For example, simvastatin and lovastatin were
reported to relax rat basilar artery, whereas pravastatin had no
effect (Bergdahl et al., 2003). This is not a consistent observation,
however, in that hydrophilic statins have also been reported to
exert effects with similar potency to their lipophilic counterparts.
For example, a recent study showed that lovastatin and pravas-
tatin stimulated endothelial NO production in bovine aortic
endothelial cells (Datar et al., 2010). Taken together, these
ﬁndings provide support for the proposition that hydrophilic
statins may require speciﬁc carrier mechanisms, present only in
certain cell types, for their uptake into cells (Generaux et al.,
2011), and furthermore, that such transporters may not be
expressed in porcine coronary artery smooth muscle cells as
hydrophilic statins had no effect in this study.
As simvastatin inhibited, rather than enhanced, the b-adreno-
ceptor-mediated relaxation of the porcine coronary artery,
we investigated the mechanism underlying this inhibition.
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through activation of adenylyl cyclase and hence an increase in
cAMP levels, as well as activation of Kþ channels through an
adenylyl cyclase-independent pathway (White et al., 2001).
Relaxations to the adenylyl cyclase activator forskolin were not
altered by simvastatin (Fig. 2), indicating that the effect of
simvastatin on b-adrenoceptor-relaxations is likely to be
mediated through an interaction with the adenylyl cyclase-
independent pathway. A study in porcine isolated coronary artery
smooth muscle cells showed that simvastatin, at similar concen-
trations to those used in this present study, inhibits BKCa channel
currents (Seto et al., 2007). This effect was not observed with
pravastatin or the Naþ salt of simvastatin, a results that is
consistent with our observations in the present study. As BKCa
channels are involved in the adenylyl cyclase-independent
mechanism of relaxation through b-adrenoceptors (White et al.,
2001), we investigated whether the inhibitory effect of simvasta-
tin on the b-adrenoceptor relaxation could be due to inhibition of
BKCa channels. We observed that simvastatin inhibited relaxa-
tions to the BKCa channel opener NS1619 (Fig. 3), indicating that
simvastatin may also block BKCa channels in intact blood vessels.
As a comparison, we found that the relaxations to the KATP
channel opener pinacidil were also inhibited, suggesting that
simvastatin may have effects on multiple Kþ channels. These
data are supported by a study in isolated coronary artery smooth
muscle cells demonstrating that simvastatin inhibits KATP channel
activity (Seto et al., 2008). In tissues pre-contracted with KCl the
salbutamol-induced relaxation was considerably reduced and
simvastatin had no further inhibitory effect on the b-adrenocep-
tor-mediated relaxation. Under these conditions of high Kþ , the
Kþ channel-mediated relaxation to salbutamol is effectively
blocked and, therefore, if simvastatin is acting to inhibit Kþ
channels, under these conditions it would have no further affect
on Kþ channel function. The fact that simvastatin does not inhibit
b-adrenoceptor-mediated relaxations under these conditions,
combined with the demonstration that simvastatin inhibits
relaxations to the Kþ channel openers, indicates that the inhibi-
tion of the b-adrenoceptor relaxation is likely to be due to
inhibition of Kþ channel activation.
In rat mesenteric arteries, acetylcholine-induced relaxations
are enhanced by simvastatin through an increase in NO signalling
(Rossoni et al., 2011). However, this was only seen in the presence
of high Kþ and not after pre-contraction with U46619. One
explanation for this could be that, in the presence of U46619,
there is a balance between the stimulation of the NO-dependent
relaxation and inhibition of the Kþ-channel mediated relaxation
by simvastatin. As such, the enhanced NO-dependent relaxation is
only seen once the Kþ-channel-mediated relaxation has been
removed and, therefore, the inhibitory effect of simvastatin is not
seen. Similarly in the results presented in this study, the inhibi-
tory effect of simvastatin on the b-adrenoceptor relaxation is not
seen in the presence of high Kþ .
The fact that pravastatin had no effect on the relaxations to
NS1619 and pinacidil (Fig. 4) is consistent with the study in isolated
coronary artery smooth muscle cells (Seto et al., 2007) and suggests
that the statins act intracellularly to inhibit Kþ channel activity,
possibly through effects on intracellular signalling pathways. In the
paper by Seto et al. (2007) it was suggested that simvastatin may
inhibit the BKCa channels by activating PKCd based on the fact that
rottlerin, a supposedly selective PKCd inhibitor, prevented the
inhibitory effect of simvastatin. However, the use of rottlerin as a
PKCd inhibitor has been questioned as it has no effect on PKCd
activity in enzyme assays, although it does inhibit other protein
kinases (Davies et al., 2000). More selective compounds are required
before it can be stated for certain that the inhibition of BKCa
channels by simvastatin is through activation of PKCd.The concentration of simvastatin used in this present study is
similar to that used in other studies to demonstrate an acute
effect of this compound on isolated blood vessels (Bergdahl et al.,
2003; Mraiche et al., 2005; Nagaoka et al., 2007). Although the
concentrations are higher than the mean plasma concentration
that would be obtained with a standard dose of 40 mg/day, drug
or nutrient interactions can lead to a 20-fold increase in plasma
levels of simvastatin (Neuvonen et al., 2008). Furthermore, tissue
accumulations of the lipophilic statins could also be considerably
higher with chronic dosing.5. Conclusion
This study demonstrates that acute application of simvastatin to
porcine coronary artery inhibits b-adrenoceptor-mediated relaxa-
tions. Simvastatin has no effect on forskolin-mediated relaxations,
indicating that the effect on b-adrenoceptor-mediated relaxations
is unlikely to be due to inhibition of an adenylyl cyclase-indepen-
dent relaxation. However, simvastatin does inhibit Kþ channel-
mediated relaxations. This, combined with previous studies in
isolated coronary artery smooth muscle cells, suggest that the
effect of simvastatin on b-adrenoceptor-mediated relaxations is
likely to be due to inhibition of Kþ channel activity.Acknowledgements
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